Coenzyme Q10 (Ubiquinol)

What coenzyme Q10 is

Coenzyme Q10 is a fat-soluble quinone that occurs in every cell and that the body makes itself. Its task in the inner mitochondrial membrane: it takes up electrons from complexes I and II and passes them on to complex III. Without this carrier, the respiratory chain – and with it ATP production – comes to a halt. This is textbook biochemistry, not a marketing story.

It does not follow that more of it is better. The German Federal Institute for Risk Assessment (BfR) explicitly does not classify coenzyme Q10 as an essential nutrient, because the healthy body makes it itself. So in healthy people, there is no deficiency in the nutritional-medicine sense. Intake becomes interesting where the body’s own synthesis is impaired.

How it is supposed to work

Two pathways are discussed. The bioenergetic one: more coenzyme Q10 in the tissue is supposed to ease electron transfer and improve ATP yield. And the antioxidant one: in its reduced form, the molecule scavenges radicals in membranes.

The first step of this chain is supported in humans: a systematic review of 24 studies in healthy adults found a consistent increase in blood concentration. The last step is not. Whether orally taken coenzyme Q10 accumulates in skeletal muscle mitochondria is considered unresolved. This gap is the reason the results diverge depending on the area of use.

Ubiquinol or ubiquinone

Coenzyme Q10 occurs in two interconvertible forms: the oxidized ubiquinone and the reduced ubiquinol. That ubiquinol is better absorbed has been measured. A randomized crossover in 12 volunteers found a geometric mean ratio of 2.20 for peak concentration compared with ubiquinone.

The conclusion that ubiquinol is therefore the clinically better choice goes beyond the data. The two trials with hard endpoints, Q-SYMBIO and KiSel-10, used ubiquinone, and an analysis of 28 clinical studies concludes that the reduction in cardiovascular mortality has been reported for ubiquinone and not for ubiquinol. Better absorption and a better outcome are two different questions.

Statins and coenzyme Q10

The most popular use is alongside statin therapy — and of all things, it is the least well supported. Statins inhibit the mevalonate pathway and thereby also lower the body’s own coenzyme Q10 synthesis. This is measurable: in 67 statin-naive patients, the plasma level fell by 43 percent after 3 months.

In the same study, however, this change did not correlate with the myopathy marker FABP3. So the obvious causal conclusion about muscle complaints does not automatically hold — and that is exactly what the intervention studies show.

What the studies show

Q-SYMBIO: two years, hard endpoints

Randomized, double-blind multicenter trial in 420 patients with moderate to severe chronic heart failure who received 100 mg of coenzyme Q10 three times daily or placebo in addition to standard therapy. The split outcome is notable: the primary short-term endpoints after 16 weeks — NYHA class, 6-minute walk test, NT-proBNP — were missed. The primary long-term endpoint after 2 years was reached: 15 percent of the CoQ10 group versus 26 percent on placebo had a major adverse cardiovascular event, hazard ratio 0.50 (95% confidence interval 0.32 to 0.80), p = 0.003. All-cause mortality was 10 percent versus 18 percent (p = 0.018).

KiSel-10: four years, but in combination

Randomized, placebo-controlled double-blind trial in 443 Swedes aged 70 to 88 who received 200 micrograms of selenium yeast and 200 mg of coenzyme Q10 daily or placebo for four years. Over 5.2 years of follow-up, cardiovascular mortality was 5.9 percent versus 12.6 percent (p = 0.015), and NT-proBNP after 48 months was 214 ng/L versus 302 ng/L (p = 0.014). The limitation lies in the design: a combination was tested in a population with low selenium status. Which share is due to coenzyme Q10 cannot be separated out.

Taylor 2015: the cleanest test of the statin question

The trial was deliberately built to be strict. First, in 120 patients with reported statin-related muscle pain, an eight-week double-blind crossover tested whether the complaints were caused by the statin at all. Only 41 passed this test and were randomized for 8 weeks to 600 mg of ubiquinol per day or placebo. Serum coenzyme Q10 rose from 1.3 to 5.2 micrograms per milliliter, so the substance did arrive. It changed nothing about the pain: p = 0.53 for pain severity, p = 0.56 for interference. Muscle strength and oxygen uptake also remained unchanged.

Where the data stop

The heart failure finding rests on a narrower base than it appears. In the Cochrane review, the result for all-cause mortality comes from 1 trial with 420 participants, all 11 included studies had an unclear or high risk of bias, and the authors conclude that there is currently no convincing evidence to support or refute its use. An independent replication of Q-SYMBIO is lacking.

For statin-related muscle complaints, the levels of evidence contradict each other. A meta-analysis of 7 studies with 389 patients finds a weighted mean difference of -0.96 for pain intensity, whose confidence interval of -1.88 to -0.03 ends just short of zero; 4 studies were significant, 3 were not. The strictest single RCT found no effect at all, and the NCCIH states that the overall evidence does not support the assumption.

For blood pressure, the result depends on how strictly the studies are filtered. A meta-analysis of 45 studies finds -3.44 mmHg systolic (95% confidence interval -5.13 to -1.55) and nothing significant diastolic. The Cochrane review on primary hypertension admitted only 2 studies with 50 participants, arrived at -3.68 mmHg (-8.86 to 1.49) and concludes that coenzyme Q10 has no clinically meaningful effect.

In healthy people, proof of a performance benefit is missing: blood levels rise reliably, but the effects on performance are small, inconsistent and no longer stable after outliers are excluded. Fertility is similar: the meta-analysis with an odds ratio of 6.02 for clinical pregnancies is contradicted by an earlier analysis that found no difference, with 69 of 426 versus 45 of 401 pregnancies. For the skin, there is only one study with 33 participants over 12 weeks: wrinkles decreased, skin moisture and dermal thickness did not.

Status, approval and legal

In Germany, coenzyme Q10 may be sold as an ingredient of food supplements; there is no approval as a medicine for heart failure or any other indication. The German Federal Institute for Risk Assessment (BfR) recommends a maximum amount of up to 100 mg per day for food supplements and advises seeking medical advice for daily doses above that. Health claims are not authorized: EFSA assessed claims such as increased performance as not scientifically substantiated. Coenzyme Q10 does not appear on the World Anti-Doping Agency’s 2026 Prohibited List.

Safety

Tolerability is well documented. In the range up to 300 mg per day, the BfR describes occasional adverse effects, mainly in the digestive system: nausea, heartburn, stomach discomfort or diarrhea, plus isolated skin rashes. Toxicologically derived were an acceptable daily intake of 12 mg per kilogram of body weight, i.e. 720 mg per day at 60 kg, and an observed safe level of 1,200 mg per day. The interactions are more important: the BfR describes the interplay with blood pressure medications and with coumarin-type anticoagulants as insufficiently studied, and cases have been described in which warfarin therapy failed under coenzyme Q10, reversibly after stopping it. The NCCIH also names insulin and advises caution with some cancer treatments; contraindications are hypersensitivity, ongoing chemotherapy and biliary obstruction. Mild insomnia has been reported from 100 mg per day — that is the documented reason not to take it in the evening. For pregnancy and breastfeeding, the official sources consulted contain no data.

Sources

• Mortensen et al., JACC Heart Failure 2014 (Q-SYMBIO)
• Al Saadi et al., Cochrane Database of Systematic Reviews 2021, CD008684
• Alehagen et al., International Journal of Cardiology 2013 (KiSel-10)
• Taylor et al., Atherosclerosis 2015
• Kovacic et al., Journal of Nutritional Science 2025
• Sandor et al., Neurology 2005
• Peng et al., Frontiers in Nutrition 2026
• Ho et al., Cochrane Database of Systematic Reviews 2016, CD007435
• Deng et al., British Journal of Nutrition 2025
• BfR, Coenzyme Q10: what is known and not known about health risks, 2023